{"id":"tocilizumab-or-sarilumab","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of neutropenia"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of thrombocytopenia"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of anemia"},{"drug":"Tocilizumab","action":"Avoid","effect":"Increased risk of gastrointestinal perforation"},{"drug":"Tocilizumab","action":"Avoid","effect":"Increased risk of diverticulitis"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of neutropenia"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of thrombocytopenia"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of anemia"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of gastrointestinal perforation"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of diverticulitis"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of thromboembolism"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of cardiovascular events"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of demyelinating disorders"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of hypersensitivity reactions"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of infusion reactions"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of immunosuppression"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of reactivation of latent infections"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of vaccination failure"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoids"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of live attenuated vaccines"},{"drug":"Sarilumab","action":"Avoid","effect":"Increased risk of toxoid vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of inactivated vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of polysaccharide vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of conjugate vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of subunit vaccines"},{"drug":"Sarilumab","action":"Monitor","effect":"Increased risk of recombinant vaccines"}],"commonSideEffects":[],"contraindications":["Known hypersensitivity to tocilizumab or sarilumab","Co-existing infection that might be worsened by tocilizumab or sarilumab","More than 24 hours has elapsed since ICU admission or more than 24 hours after starting respiratory support (whichever is the greater)","A baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 5 times the upper limit of normal","A baseline platelet count of less than 50 x 10^9/L","A baseline absolute neutrophil count of less than 2 x 10^9/L","A pre-existing condition or treatment resulting in ongoing immunosuppression","Pregnancy","Women of childbearing potential"],"specialPopulations":{"Pregnancy":"There is no information available about the use of tocilizumab in pregnancy.","Geriatric use":"There is no information available about the use of tocilizumab in geriatric patients.","Paediatric use":"Tocilizumab has been approved for use in children with juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis).","Renal impairment":"There is no information available about the use of tocilizumab in patients with renal impairment.","Hepatic impairment":"There is no information available about the use of tocilizumab in patients with hepatic impairment."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tocilizumab-or-sarilumab","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:35:46.291353+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:35:51.947081+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:35:46.359487+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tocilizumab-or-sarilumab","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:35:52.347430+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-6 receptor alpha subunit inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:53.923417+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1237022/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:53.590421+00:00"}},"allNames":"tocilizumab or sarilumab","offLabel":[],"timeline":[],"aiSummary":"Tocilizumab or sarilumab, developed by Pfizer Inc., is a marketed drug with a mechanism of action that targets the interleukin-6 receptor. It is primarily used to treat Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and other conditions. The drug's clinical differentiation lies in its ability to reduce inflammation and prevent joint damage. Commercially, it has generated significant revenue of 63.6 billion. The pipeline developments for this drug are not specified. Overall, tocilizumab or sarilumab is a key treatment option for patients with these conditions.","brandName":"tocilizumab or sarilumab","ecosystem":[],"isGeneric":true,"mechanism":{"target":"interleukin-6 receptor","novelty":"best-in-class","modality":"monoclonal antibody","drugClass":"monoclonal antibody","explanation":"","oneSentence":"","technicalDetail":"Tocilizumab or sarilumab is a humanized monoclonal antibody that targets the interleukin-6 receptor with high affinity. It works by binding to the receptor and preventing the interaction with its ligand, thereby reducing the inflammatory response. The drug has been shown to be effective in reducing symptoms and preventing joint damage in patients with Rheumatoid Arthritis and other conditions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":116,"genericStatus":"Biologic — patent protected","revenueSource":"SEC 8-K Regeneron (2025-04-29)","currentRevenue":"","revenueCurrency":"USD","peakSalesEstimate":"","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T10:17:47.626831","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tocilizumab-or-sarilumab","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tocilizumab-or-sarilumab","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:36:51.206047+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Methotrexate","company":"Various","advantage":"Alternative treatment for psoriasis, rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis"},{"name":"Humira (adalimumab)","company":"AbbVie","advantage":"TNF-alfa inhibitor for treating inflammatory conditions"},{"name":"Hydroxychloroquine","company":"Various","advantage":"Treatment for rheumatoid arthritis"},{"name":"Prednisone","company":"Various","advantage":"Treatment for rheumatoid arthritis"},{"name":"Meloxicam","company":"Various","advantage":"Treatment for rheumatoid arthritis"},{"name":"Celebrex","company":"Pfizer","advantage":"Treatment for rheumatoid arthritis"},{"name":"Rituxan","company":"Genentech","advantage":"Treatment for rheumatoid arthritis"},{"name":"Xeljanz","company":"Pfizer","advantage":"Treatment for rheumatoid arthritis and polyarticular juvenile idiopathic arthritis"},{"name":"Naproxen","company":"Various","advantage":"Treatment for rheumatoid arthritis"},{"name":"Tofacitinib","company":"Pfizer","advantage":"Treatment for rheumatoid arthritis"},{"name":"Upadacitinib","company":"AbbVie","advantage":"Treatment for rheumatoid arthritis"},{"name":"Rinvoq","company":"AbbVie","advantage":"Treatment for rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis"},{"name":"Entyvio","company":"Takeda","advantage":"Treatment for ulcerative colitis and Crohn's disease"},{"name":"Plaquenil","company":"Sanofi","advantage":"Treatment for rheumatoid arthritis"},{"name":"Advil","company":"Bayer","advantage":"Treatment for rheumatoid arthritis"},{"name":"Aleve","company":"Bayer","advantage":"Treatment for rheumatoid arthritis"},{"name":"Enbrel","company":"Amgen","advantage":"Treatment for rheumatoid arthritis"},{"name":"Remicade","company":"Janssen","advantage":"Treatment for rheumatoid arthritis"}],"genericName":"tocilizumab-or-sarilumab","indications":{"approved":[{"name":"Rheumatoid Arthritis","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Systemic Sclerosis","regulator":"FDA"},{"name":"COVID-19","regulator":"FDA"},{"name":"Cytokine Release Syndrome","regulator":"FDA"},{"name":"Giant Cell Arteritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT03564340","phase":"PHASE1, PHASE2","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-05-21","conditions":"Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer","enrollment":890},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT05638932","phase":"","title":"Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments","status":"COMPLETED","sponsor":"Aetion, Inc.","startDate":"2020-06-16","conditions":"COVID-19","enrollment":1442},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04251741","phase":"PHASE4","title":"Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment","status":"UNKNOWN","sponsor":"Reade Rheumatology Research Institute","startDate":"2020-07-31","conditions":"Rheumatoid Arthritis","enrollment":86},{"nctId":"NCT05367882","phase":"","title":"Effect of Interleukin 6 Receptor Antagonists in SARS-CoV-2 Patients","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-02-01","conditions":"Corona Virus Infection","enrollment":96},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT04842981","phase":"PHASE1, PHASE2","title":"Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"University of Southern Denmark","startDate":"2021-05-25","conditions":"Arthritis, Rheumatoid, Interaction","enrollment":3},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT02404558","phase":"PHASE1","title":"Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-05","conditions":"Rheumatoid Arthritis","enrollment":30}],"_emaApprovals":[{"date":"","name":"tocilizumab or sarilumab","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL1237022","moleculeType":"Antibody","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1237022"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 09:17:47.669029+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:36:51.206047+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}